- Home
- SND vs LXEO Comparison
SND vs LXEO Comparison
Compare SND & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SND
- LXEO
- Stock Information
- Founded
- SND 2011
- LXEO 2017
- Country
- SND United States
- LXEO United States
- Employees
- SND N/A
- LXEO N/A
- Industry
- SND Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- LXEO
- Sector
- SND Industrials
- LXEO
- Exchange
- SND Nasdaq
- LXEO Nasdaq
- Market Cap
- SND 91.3M
- LXEO 93.9M
- IPO Year
- SND 2016
- LXEO 2023
- Fundamental
- Price
- SND $2.05
- LXEO $4.49
- Analyst Decision
- SND Hold
- LXEO Strong Buy
- Analyst Count
- SND 1
- LXEO 5
- Target Price
- SND $2.25
- LXEO $16.60
- AVG Volume (30 Days)
- SND 83.3K
- LXEO 520.2K
- Earning Date
- SND 08-12-2025
- LXEO 08-11-2025
- Dividend Yield
- SND 4.83%
- LXEO N/A
- EPS Growth
- SND N/A
- LXEO N/A
- EPS
- SND N/A
- LXEO N/A
- Revenue
- SND $293,878,000.00
- LXEO N/A
- Revenue This Year
- SND N/A
- LXEO N/A
- Revenue Next Year
- SND N/A
- LXEO N/A
- P/E Ratio
- SND N/A
- LXEO N/A
- Revenue Growth
- SND N/A
- LXEO N/A
- 52 Week Low
- SND $1.73
- LXEO $1.45
- 52 Week High
- SND $2.80
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- SND 55.50
- LXEO 63.76
- Support Level
- SND $1.91
- LXEO $3.91
- Resistance Level
- SND $2.04
- LXEO $4.85
- Average True Range (ATR)
- SND 0.08
- LXEO 0.33
- MACD
- SND -0.00
- LXEO 0.02
- Stochastic Oscillator
- SND 60.00
- LXEO 78.69
About SND Smart Sand Inc.
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.